PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-10.89%
Negative revenue growth while MRVL stands at 10.88%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-14.65%
Negative gross profit growth while MRVL is at 16.78%. Joel Greenblatt would examine cost competitiveness or demand decline.
-17.85%
Negative EBIT growth while MRVL is at 203.93%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-18.75%
Negative operating income growth while MRVL is at 203.93%. Joel Greenblatt would press for urgent turnaround measures.
-14.51%
Negative net income growth while MRVL stands at 109.86%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-13.94%
Negative EPS growth while MRVL is at 113.25%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-13.77%
Negative diluted EPS growth while MRVL is at 113.25%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.77%
Share reduction while MRVL is at 1.91%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.76%
Reduced diluted shares while MRVL is at 4.04%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
7.68%
Maintaining or increasing dividends while MRVL cut them. John Neff might see a strong edge in shareholder returns.
-26.17%
Negative OCF growth while MRVL is at 30.85%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-45.60%
Negative FCF growth while MRVL is at 61.54%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
92.58%
10Y revenue/share CAGR above 1.5x MRVL's 24.94%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
35.39%
5Y revenue/share CAGR at 75-90% of MRVL's 41.35%. Bill Ackman would encourage strategies to match competitor’s pace.
43.56%
3Y revenue/share CAGR similar to MRVL's 40.47%. Walter Schloss would assume both companies experience comparable short-term cycles.
131.20%
10Y OCF/share CAGR at 50-75% of MRVL's 246.32%. Martin Whitman might fear a structural deficiency in operational efficiency.
15.09%
Below 50% of MRVL's 75.25%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
19.89%
3Y OCF/share CAGR under 50% of MRVL's 153.00%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
812.98%
Positive 10Y CAGR while MRVL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
520.08%
5Y net income/share CAGR above 1.5x MRVL's 104.63%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
88.83%
3Y net income/share CAGR 75-90% of MRVL's 101.84%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
63.37%
10Y equity/share CAGR at 50-75% of MRVL's 116.39%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
53.31%
Below 50% of MRVL's 134.46%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
68.54%
3Y equity/share CAGR similar to MRVL's 67.42%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
487.06%
Dividend/share CAGR of 487.06% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
99.82%
5Y dividend/share CAGR above 1.5x MRVL's 0.17%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
37.51%
3Y dividend/share CAGR above 1.5x MRVL's 0.08%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-7.11%
Firm’s AR is declining while MRVL shows 7.19%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
14.68%
Inventory growth well above MRVL's 14.59%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
4.41%
Asset growth above 1.5x MRVL's 0.41%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
1.26%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
14.39%
We have some new debt while MRVL reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
0.70%
R&D dropping or stable vs. MRVL's 7.36%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-0.46%
We cut SG&A while MRVL invests at 3.21%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.